Quest Diagnostics (NYSE:DGX) delivered a robust fourth-quarter beat on Tuesday, February 10, 2026, as the company’s pivot toward high-growth hospital partnerships and consumer wellness testing pushed annual revenue past the $11 billion milestone.
The Secaucus, New Jersey-based lab leader reported fourth-quarter adjusted earnings of $2.42 per share, topping the $2.36 analyst consensus.
Revenue for the quarter rose 7.1% to $2.81 billion, fueled by an 8.5% jump in requisition volume.
The 2025 fiscal year marked a period of aggressive expansion for Quest, which integrated eight acquisitions and launched its largest-ever "Co-Lab Solutions" implementation for Corewell Health in Michigan.
This strategy of acting as the "lab engine" for health systems, combined with new dialysis testing services for Fresenius Medical Care, drove full-year revenue up 11.8% to $11.04 billion.
CEO Jim Davis noted that the company’s "clinical innovation" strategy—including new Alzheimer's and oncology diagnostics—is successfully fulfilling the needs of both traditional clinicians and a new wave of digital wellness customers through partnerships with Oura and Whoop.
Looking ahead to 2026, the company issued a confident revenue forecast of $11.70 billion to $11.82 billion, which sits well above the $11.39 billion the Street had projected.